降脂治疗与出血性卒中风险:他汀与PCSK9抑制剂的比较荟萃分析
他汀与出血性卒中风险增加相关(相对风险1.15,P=0.04),PCSK9抑制剂不增加风险(P=0.77)。高剂量/效力他汀风险更高(相对风险1.53,P=0.002),且有缺血性卒中/短暂性脑缺血发作病史者风险放大(相对风险1.43,P=0.04)。
要点
- 他汀增加出血性卒中风险,呈剂量和既往脑血管损伤类型依赖。
- PCSK9抑制剂不增加出血性卒中风险。
- 高出血性卒中风险患者可优先考虑PCSK9抑制剂。
核心结论
- 他汀以药物剂量和指数脑血管损伤类型依赖的方式增加出血性卒中风险。
- PCSK9抑制剂不增加出血性卒中风险。
- PCSK9抑制剂可能是出血性卒中高风险患者(包括既往出血性卒中)的首选降脂药物类别。
研究设计与样本
- 系统比较荟萃分析,遵循PRISMA指南,评估所有已完成且治疗超过3个月的他汀和PCSK9抑制剂随机临床试验的出血性卒中发生率。
主要发现
- 在所有患者类型和所有药物剂量/效力下,他汀与出血性卒中风险增加相关:相对风险1.15,P=0.04;PCSK9抑制剂不增加风险(P=0.77)。
- 他汀分析中(5项试验,9772例患者),既往缺血性卒中/短暂性脑缺血发作与出血性卒中风险放大相关:相对风险1.43,P=0.04;指数脑出血与复发性出血性卒中风险极高相关:风险比4.06。
- PCSK9抑制剂分析中,既往缺血性卒中/短暂性脑缺血发作(1项试验,5337例患者)与出血性卒中风险增加无关(P=0.97)。
关键数值与推荐
- 他汀与出血性卒中风险增加相关:相对风险1.15,P=0.04。
- 高剂量/效力他汀与出血性卒中风险放大相关:相对风险1.53,P=0.002。
- 他汀使用者中,既往缺血性卒中/短暂性脑缺血发作与出血性卒中风险放大相关:相对风险1.43,P=0.04。
- 他汀使用者中,指数脑出血与复发性出血性卒中风险极高相关:风险比4.06。
- PCSK9抑制剂与出血性卒中风险增加无关(P=0.77),高剂量/效力PCSK9抑制剂亦不增加风险(P=0.99)。
临床怎么用
- 对于出血性卒中高风险患者,包括既往出血性卒中患者,可优先考虑使用PCSK9抑制剂而非他汀。
- 使用他汀时应考虑剂量/效力对出血性卒中风险的影响,尤其在高剂量/效力时。
- 对有缺血性卒中/短暂性脑缺血发作病史的患者,使用他汀需警惕出血性卒中风险放大。
局限性
- 他汀与PCSK9抑制剂的比较基于各自随机临床试验的间接比较,非头对头试验。
- 部分分析基于少量试验,如高剂量/效力PCSK9抑制剂仅1项试验。
- 研究为荟萃分析,可能存在纳入试验的异质性和发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Statins were shown to increase hemorrhagic stroke (HS) in patients with a first cerebrovascular event in 2006 (SPARCL), likely due to off-target antithrombotic effects, but continued to sometimes be used in patients with elevated HS risk due to absence of alternative medications. Recently, the PCSK9Is (proprotein convertase subtilisin kexin 9 inhibitors) have become available as a potent lipid-lowering class with potentially less hemorrhagic propensity. METHODS: We performed a systematic comparative meta-analysis assessing HS rates across all completed statin and PCSK9I randomized clinical trials with treatment >3 months, following PRISMA guidelines. In addition to HS rates across all trials, causal relation was probed by evaluating for dose-response relationships by medication (low versus high medication dose/potency) and by presence and type of preceding brain vascular events at inception (none versus ischemic stroke/transient ischemic attack versus HS). RESULTS: The systematic review identified 36 statin randomized clinical trials (204 918 patients) and 5 PCSK9I randomized clinical trials (76 140 patients). Across all patient types and all medication doses/potencies, statins were associated with increased HS: relative risk 1.15, P=0.04; PCSK9Is were not (P=0.77). In the medication dose/potency analysis, higher dose/potency statins (7 trials, 62 204 patients) were associated with magnified HS risk: relative risk, 1.53; P=0.002; higher dose/potency PCSK9Is (1 trial, 27 564 patients) were not (P=0.99). In the type of index brain vascular injury analysis for statins (5 trials, 9772 patients), prior ischemic stroke/transient ischemic attack was associated with a magnified risk of HS: relative risk, 1.43; P=0.04; and index intracerebral hemorrhage was associated with an extremely high effect estimate of risk of recurrent HS: hazard ratio, 4.06. For PCSK9Is, prior ischemic stroke/transient ischemic attack (1 trial, 5337 patients) was not associated with increased HS risk (P=0.97). CONCLUSIONS: Statins increase the risk of HS in a medication dose- and type of index brain vascular injury-dependent manner; PCSK9Is do not increase HS risk. PCSK9Is may be a preferred lipid-lowering medication class in patients with elevated HS risk, including patients with prior HS.
引用
- Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke. 2021. PMID: 34154390. doi:10.1161/STROKEAHA.121.034576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。